Intra-Cellular Therapies Q3 2024 GAAP EPS $(0.25) Misses $(0.20) Estimate, Sales $175.375M Beat $172.352M Estimate
Portfolio Pulse from Benzinga Newsdesk
Intra-Cellular Therapies reported a Q3 2024 GAAP EPS of $(0.25), missing the $(0.20) estimate, but sales of $175.375M beat the $172.352M estimate, marking a 39% increase from last year.
October 30, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Intra-Cellular Therapies' Q3 2024 earnings report showed a miss on EPS but a beat on sales, with a significant 39% year-over-year sales increase.
The EPS miss indicates potential concerns about profitability, but the sales beat and significant year-over-year growth suggest strong revenue performance. The mixed results may lead to neutral short-term stock price movement as investors weigh the earnings miss against the sales growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100